Neurol. praxi. 2024;25(2):108-115 | DOI: 10.36290/neu.2023.084

Markers of neurodegenerative dementias: the contribution of neuroimaging and neurophysiological methods

David Ondráček1, 3, Mgr. Žaneta Železníková1, 2, MUDr. Zuzana Balážová, Ph.D.1, Ing. Martin Lamoš, Ph.D.1, prof. MUDr. Irena Rektorová, Ph.D.1, 2
1 Středoevropský technologický institut - CEITEC, Centrum neurověd, Masarykova univerzita, Brno
2 1. neurologická klinika, LF MU a FN u sv. Anny, Brno
3 Lékařská fakulta Masarykovy univerzity, Brno

There has been a great development in imaging methods and their use for early diagnosis of neurodegenerative disorders. The aim is to discover more sensitive biomarkers that would enable early stratification of dementia subtypes and disease prognosis. There are various types of imaging methods such as nuclear medicine (SPECT, PET), MRI and electrophysiology (EEG), which provide complementary picture about degenerative diseases. The main purpose of this work is to review the most typical findings in neurodegenerative dementia and their most common variants and subtypes. Although some of them are suitable only for scientific purposes, many have been utilized in diagnostic guidelines.

Keywords: SPECT, PET, MRI, EEG, neurodegenerative disorders, Alzheimer's disease, dementia with Lewy bodies, mild cognitive impairment.

Received: November 30, 2023; Revised: December 24, 2023; Accepted: December 29, 2023; Prepublished online: December 29, 2023; Published: April 16, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ondráček D, Železníková Ž, Balážová Z, Lamoš M, Rektorová I. Markers of neurodegenerative dementias: the contribution of neuroimaging and neurophysiological methods. Neurol. praxi. 2024;25(2):108-115. doi: 10.36290/neu.2023.084.
Download citation

LMm_References

  1. Bonanni L, Perfetti B, Bifolchetti S, et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. Neurobiol Aging. 2015;36(1):434. doi:10.1016/J.NEUROBIOLAGING.2014. 07. 009. Go to original source...
  2. Cséfalvay Z, Bajtošová R, Keller J, et al. Primary progressive aphasia. Cesk Slov Neurol N. 2020;83(3):226-239. doi:10.14735/AMCSNN2020226. Go to original source...
  3. Donaghy PC, Carrarini C, Ferreira D, et al. Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta­‑analysis. Alzheimer's & Dementia. 2023;19(7):3186-3202. doi:10.1002/ALZ.13105. Go to original source... Go to PubMed...
  4. Elder GJ, Lazar AS, Alfonso­‑Miller P, et al. Sleep disturbances in Lewy body dementia: A systematic review. Int J Geriatr Psychiatry. 2022;37(10):10.1002/gps.5814. doi: 10.1002/gps.5814. PMID: 36168299; PMCID: PMC9827922. Go to original source... Go to PubMed...
  5. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology. 1988;38(12):1822-5. doi: 10.1212/wnl.38. 12. 1822. PMID: 3057397. Go to original source...
  6. Ferreira D, Verhagen C, Hernández­‑Cabrera JA, et al. Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Sci Rep. 2017;7. doi:10.1038/SREP46263. Go to original source... Go to PubMed...
  7. Gorno­‑Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006. doi:10.1212/WNL.0B013E31821103E6. Go to original source... Go to PubMed...
  8. Hansen N, Bouter C, Müller SJ, et al. New Insights into Potential Biomarkers in Patients with Mild Cognitive Impairment Occurring in the Prodromal Stage of Dementia with Lewy Bodies. Brain Sci. 2023;13(2). doi:10.3390/BRAINSCI13020242. Go to original source... Go to PubMed...
  9. Hou R, Beardmore R, Holmes C, et al. A case­‑control study of the locus coeruleus degeneration in Alzheimer's disease. European Neuropsychopharmacology. 2021;43:153-159. doi:10.1016/J.EURONEURO.2020. 12. 013. Go to original source...
  10. Chougar L, Arsovic E, Gaurav R, et al. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism. Movement Disorders. 2022;37(6):1245-1255. doi:10.1002/MDS.28988. Go to original source... Go to PubMed...
  11. Jack CR, Bennett DA, Blennow K, et al. NIA­‑AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535. doi:10.1016/J.JALZ.2018. 02. 018. Go to original source...
  12. Laczó J, Hort J, Vyhnálek M. Hodnocení atrofie mozku pomocí vizuálních škál a jejich klinický přínos pro časnou a diferenciální diagnostiku demencí. Neurol Praxi. 2021;22(5):358-374. doi:10.36290/NEU.2021.026. Go to original source...
  13. Lamoš M, Morávková I, Ondráček D, et al. Altered Spatiotemporal Dynamics of the Resting Brain in Mild Cognitive Impairment with Lewy Bodies. Movement Disorders. 2021;36(10):2435-2440. doi:10.1002/MDS.28741. Go to original source... Go to PubMed...
  14. Lejko N, Larabi DI, Herrmann CS, et al. Alpha Power and Functional Connectivity in Cognitive Decline: A Systematic Review and Meta­‑Analysis. Journal of Alzheimer's Disease. 2020;78(3):1047. doi:10.3233/JAD-200962. Go to original source... Go to PubMed...
  15. Ma Y, Zhang S, Li J, et al. Predictive Accuracy of Amyloid Imaging for Progression From Mild Cognitive Impairment to Alzheimer Disease With Different Lengths of Follow­‑up: A Meta­‑analysis. Medicine. 2014;93(27). doi:10.1097/MD.0000000000000150. Go to original source... Go to PubMed...
  16. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I­‑FP­‑CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology. 2007;6(4):305-313. doi:10.1016/S1474-4422(07)70057-1. Go to original source... Go to PubMed...
  17. Mckeith I, Taylor JP, Thomas A, et al. Revisiting DLB Diagnosis: A Consideration of Prodromal DLB and of the Diagnostic Overlap With Alzheimer Disease. J Geriatr Psychiatry Neurol. 2016;29(5):249-253. doi:10.1177/0891988716656083. Go to original source... Go to PubMed...
  18. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743. doi:10.1212/WNL.0000000000009323. Go to original source... Go to PubMed...
  19. Michel CM, Koenig T. EEG microstates as a tool for studying the temporal dynamics of whole­‑brain neuronal networks: a review. Neuroimage. 2018;180:577-593. doi:10.1016/J.NEUROIMAGE.2017. 11. 062. Go to original source...
  20. Minoshima S, Drzezga AE, Cochairs, et al. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1. 0. Published online 2016. doi:10.2967/jnumed.116.174615. Go to original source... Go to PubMed...
  21. Minoshima S, Mosci K, Cross D, et al. Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders. Semin Nucl Med. 2021;51(3):230-240. doi:10.1053/J.SEMNUCLMED.2021. 01. 002. Go to original source...
  22. Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F­‑fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201-1217. doi:10.1111/ENE.13728. Go to original source... Go to PubMed...
  23. Ossenkoppele R, Lyoo CH, Jester­‑Broms J, et al. Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurol. 2020;77(5):1. doi:10.1001/JAMANEUROL.2019.5154. Go to original source... Go to PubMed...
  24. Peralta C, Strafella AP, van Eimeren T, et al. Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms. Mov Disord Clin Pract. 2022;9(1):6. doi:10.1002/MDC3.13354 Go to original source... Go to PubMed...
  25. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744. doi:10.1093/BRAIN/AWZ030. Go to original source... Go to PubMed...
  26. Prasuhn J, Prasuhn M, Fellbrich A, et al. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease. Neurology. 2021;97(10):e1007-e1016. doi:10.1212/WNL.0000000000012444. Go to original source... Go to PubMed...
  27. Pyrgelis ES, Velonakis G, Papageorgiou SG, et al. Imaging Markers for Normal Pressure Hydrocephalus: An Overview. Biomedicines. 2023;11(5):1265. doi:10.3390/BIOMEDICINES11051265. Go to original source... Go to PubMed...
  28. Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0 T susceptibility­‑weighted imaging in neurodegenerative Parkinsonism. Movement Disorders. 2015;30(8):1068-1076. doi:10.1002/MDS.26171. Go to original source... Go to PubMed...
  29. Rohan Z, Matěj R, Rusina R. Překrývání neurodegenerativních demencí. Cesk Slov Neurol N. 2015;78(6):641-648. doi:10.14735/AMCSNN2015641. Go to original source...
  30. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport. 2006;17(11):1215-1218. doi:10.1097/01.WNR.0000227984.84927.A7. Go to original source... Go to PubMed...
  31. Sejnoha Minsterova A, Klobusiakova P, Pies A, et al. Patterns of diffusion kurtosis changes in Parkinson's disease subtypes. Parkinsonism Relat Disord. 2020;81:96-102. doi:10.1016/j.parkreldis.2020. 10. 032. Go to original source...
  32. Shimizu S, Hirao K, Kanetaka H, et al. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2016;43(1):184. doi:10.1007/S00259-015-3146-Y. Go to original source... Go to PubMed...
  33. Taximaimaiti R, Luo X, Wang XP. Pharmacological and Non­‑pharmacological Treatments of Sleep Disorders in Parkinson's Disease. Curr Neuropharmacol. 2021;19(12):2233-2249. doi: 10.2174/1570159X19666210517115706. PMID: 33998990; PMCID: PMC9185775. Go to original source... Go to PubMed...
  34. van der Zande JJ, Gouw AA, Steenoven I van, et al. EEG Characteristics of Dementia With Lewy Bodies, Alzheimer's Disease and Mixed Pathology. Front Aging Neurosci. 2018;10(JUL). doi:10.3389/FNAGI.2018.00190. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.